Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children

About 4-10% of children and adolescents suffer from migraine. In the last few years, several studies have been performed to assess the efficacy and safety of triptans for the acute treatment of migraine in children and adolescents. Only sumatriptan nasal spray has been approved for the treatment of acute migraine with or without aura in adolescents aged 12-17 years in Europe. This review describes the results of the studies with sumatriptan nasal spray that have been performed in children and adolescents, including a study performed in the Netherlands.     

Efficacy and onset of action of fluticasone propionate aqueous nasal spray on nasal symptoms, eosinophil count, and mediator release after nasal allergen challenge in patients with seasonal allergic rhinitis

We studied the effect and onset of action of fluticasone propionate aqueous nasal spray (FPANS) on mediator release and eosinophil accumulation in nasal secretions and on nasal symptoms of patients with seasonal allergic rhinitis after nasal allergen challenge (NAC). At the end of the pollen season, 28 patients were randomized in a double-blind and crossover design to receive 7 days' treatment with FPANS (200 μg, once daily) and matching placebo. NACs were performed before and at 6 h and 1. 2. 3. and 7 days during treatment with FPANS or placebo. Nasal secretions were collected for a quantitative determination of mediators and eosinophil count before and 5 min after each challenge. Nasal symptoms were assessed by scales grading the severity of symptoms at the same time. Results showed that for mediator concentrations there was a significant decrease of leukotriene C4 (P<0.001) at 7 days after the first administration of FPANS as compared to placebo. Two days after FPANS. both eosinophil counts and eosinophil cationic protein (ECP) concentrations were lower than those of placebo (eosinophils; f=0.032; ECP; F=0.038). The onset became even more important at day 7 (eosinophils; P=0.001; ECP; P=0.009) during the FPANS treatment period. For the subjective nasal symptoms, a significant reduction of symptom scores for nasal obstruction occurred also at day 3 (F=0.017) and for sneezing at day 7 (f=0.003). There was not yet any significant improvement of the objective nasal airway resistance after the different NACs during the study period. In conclusion, this study demonstrated that topical fluticasone propionate is effective in the treatment of mucosal inflammation induced by NAC. For optimal control of nasal symptoms induced by repeated maximal allergen challenges, a treatment period of more than 1 week is required.     

Cat shedding of Fel d I is not reduced by washings, Allerpet-C spray, or acepromazine

Background: No published studies have compared the effectiveness of several treatments proposed to reduce cat allergenicity. Cat washing studies demonstrating efficacy involved very small sample sizes or infrequent washings. Allerpet-C (Allerpet, Inc., New York, N.Y.), a widely advertised topical spray, and acepromazine, a tranquilizer advocated as efficacious in subsedating doses, have never been scientifically studied. Objective: We compared the effects of cat washing, Allerpet-C spray, and acepromazine with that of no treatment on the shedding of the primary cat allergen, Felis domesticus I by cats. Methods: In a blinded, comparative, controlled study, we measured the amounts of Fel d I shed during an 8-week treatment period with a sample of 24 female mongrel cats randomly assigned to four groups; one group received weekly distilled water washings, one received weekly Allerpet-C spray applications, one received daily oral acepromazine, and one had no treatment (control). Thirty-minute, twice-weekly air samples were collected from each cat with a laminated plastic–acrylic chamber and air sampler. Results: One-sample, two-sided t tests comparing baseline to final-week measurements revealed no significant change in Fel d I within each group (mean change ±SD: washing; 487.6 ± 1896.4 mU per 30 minutes, p = 0.63; Allerpet-C spray, 429.2 ± 871.6 mU per 30 minutes, p = 0.46 acepromazine; −620.6 ± 1031.2, p = 0.52 per 30 minutes). Furthermore, analysis of covariance revealed no significant change in Fel d I levels between groups (p = 0.72). Conclusions: Our data do not show significant reductions in Fel d I shedding as a result of any of these treatments. Therefore we cannot recommend them to patients allergic to cats. (J ALLERGY CLIN IMMUNOL 1995;95:1164-71.)     

山药配方颗粒溶化性差的原因分析与解决策略

山药配方颗粒由山药饮片经水煎煮提取、分离、浓缩、干燥、制粒而成,具有调剂简单、使用方便、免煎易服等优势。然而,因山药富含淀粉与黏液质类成分,其提取物粉末与配方颗粒溶化性差,在5 min内难以完全溶化或分散,不溶物即使在水中静置24 h也难以完全溶散,影响了配方颗粒的质量评价与患者的服药心理。因此,通过研究山药提取物及其配方颗粒的溶化过程与机制,发现山药特殊的化学组成、高温提取过程中淀粉的变性及其与蛋白质等物质的复合、喷雾干燥过程中“衣膜”的收缩形成等因素综合叠加,最终形成“衣膜”包覆淀粉粒的特殊微观结构,是山药配方颗粒溶化性差的根本原因。基于课题组前期对粉体结构-性质-功能的研究,笔者提出采用粉体改性工艺改善山药配方颗粒溶化性的技术策略,并通过实验证明改性处理后的山药配方颗粒能在2 min内实现全部溶散,解决了该技术难题,可为其他类似品种的溶化性改善提供借鉴,推动中药配方颗粒产业的高质量发展。     

丹参桐固体分散物的研究

应用聚乙烯吡喀烷酮（PVP）为载体,采用喷雾干燥制备了丹参酮（Tanshinone TAN)的固体分散物。测定了TAN原料药、固体分散物以及机械混合物的体外溶出度,并通过X－射线衍射、扫描电观察、以及用红光光谱和紫外光谱分析对固体分散物进行了研究。结果表明,TAN固体分散物的溶出度与TAN原料药和机械混合物相比有显著提高;TAN以超细态分散于载体中;TAN分子和载体分子之间未发生化学反应。     

基于熵权法评价干燥方法对经典名方华盖散基准样品质量属性的影响

目的 优选经典名方华盖散基准样品的干燥方法。方法 采用真空干燥、真空带式干燥、喷雾干燥、冷冻干燥方法制备华盖散基准样品,应用扫描电子显微镜、差式扫描量热分析、HPLC等方法测定基准样品的质量属性,以得粉率、玻璃化转变温度及成分含量转移率等为评价指标,运用熵权法对各指标赋予权重进行综合评价。结果 喷雾干燥基准样品粒子呈类球形、粒径最小,冷冻干燥基准样品不规则、蓬松、溶化性好。指标成分盐酸麻黄总碱、苦杏仁苷、橙皮苷、甘草苷、甘草酸转移率分别为85.66%～104.78%、90.81%～104.16%、91.42%～94.86%、83.98%～94.69%、87.85%～94.45%,指纹图谱相似度均大于0.9。结论 经综合评价得出冷冻干燥方法最佳,3批验证工艺重复性、可行性较好,为经典名方基准样品质量属性研究提供了理论依据和实践价值。     

表面改性与致孔对干姜醇提物压片关键性能改善的研究

目的 以干姜Zingiberis Rhizoma醇提物为研究对象,研究表面改性、聚集与致孔相结合的共处理方式改善干姜醇提物的压片关键性能。方法 以共聚维酮（plasdone S-630,PVP/VA）和碳酸氢铵分别为改性剂和致孔剂,采用喷雾干燥共处理方法制备不同比例的干姜醇提物改性复合粉体,测定并比较各粉体的密度、流动性、粒径、孔隙率和压缩性等粉体学性质和抗张强度、屈服压、功和能等相关压片性质,并采用扫描电子显微镜（SEM）对各粒子表面形态进行表征。结果 仅加入共聚维酮或碳酸氢铵制备的复合粒子的孔隙率、抗张强度（TS）、有效功（Esp）和能（E2）均优于原粉粒子。此外,相比于碳酸氢铵或共聚维酮单独制备的复合粒子,碳酸氢铵-共聚维酮（7.0%、14.0%、21.0%）共喷雾制备的复合粒子所压制片剂的抗张强度进一步提升：分别为（1）3.8～9.7、4.0～12.5、4.2～13.7倍和（2）1.5～2.1、1.3～2.2、1.2～1.8倍。即同时加入共聚维酮和碳酸氢铵制备的多孔复合粒子使上述性质得到进一步改善。另外,崩解时间会随共聚维酮加入而有所延长（9～14 min）,碳酸氢铵的致孔作用...     

水飞蓟素固体分散体中水飞蓟宾溶出速度的研究

[目的 ]研究载体和表面活性剂对水飞蓟素固体分散体中水飞蓟宾溶出速度的影响 .[方法 ]采用熔融法制备水飞蓟素固体分散体 ,观察固体分散体中水飞蓟宾在人工肠液中的累积溶出量变化 .[结果 ]水飞蓟素与聚乙二醇为 1∶9比例时固体分散体中水飞蓟宾的溶出速率最佳 ,其最大累积溶出率为6 4 2 7% ;表面活性剂十二烷基硫酸钠组固体分散体的累积溶出率为 6 4 48% .[结论 ]与原料药物相比 ,以聚乙二醇为载体的固体分散体提高了水飞蓟宾的溶出速率     

液相色谱质谱联用(LC-MS/MS)在天然化学成分分析中的应用Ⅰ.音喷离子化(SSI)与大气压化学离子化(APCI)对利血平的比较分析

报道应用 L C- MS/ MS,采用音喷离子化 (SSI)与大气压化学离子化 (APCI)对利血平的比较分析 ,应用这两种离子化方法比较所得的利血平的标准质谱 (MS)和二级质谱 (MS2 ) ,实验证明两种离子化方法所得结果完全一致     

喷雾干燥对溶菌酶一级结构的影响

目的 考察喷雾干燥对溶茵酶一级结构稳定性的影响。方法 以送料速度2.4 ml/min、进口气流温度150℃、出口气流温度70℃、雾化器转速18 000 r/min制备喷雾干燥溶茵酶。采用MALDI-TOF/MS测定喷雾干燥对溶菌酶一级结构的影响。结果 喷雾干燥溶菌酶除了具有溶菌酶相同的准分子离子峰、二聚体、三聚体、四聚体及三聚体的两电荷离子峰外,另多5个碎片离子峰。结论 喷雾干燥可造成溶菌酶一级结构破坏。